Trial Profile
To Determine Excretion and whole-body retention of radium-223 dichloride administered for the treatment of bone metastases from castration resistant prostate cancer
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 31 Aug 2018
Price :
$35
*
At a glance
- Drugs Radium 223 chloride (Primary)
- Indications Bone metastases; Prostate cancer
- Focus Therapeutic Use
- 31 Aug 2018 New trial record